MDK-NCL and MDK–syndecan interactions between tumor cells, stromal cells, and immune cells were found to be increased in tumors with acquired resistance to CDK4/6 inhibitors, though it was not associated with intrinsic resistance and early progression [125]. This evidence concerns the gene SDC1 and neoplasm.